Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina.

Felizzia G, Segatori VI, Galluzzo L, Alonso DF, Pinto N, Sobrero V, Varela M, Verón D, Gulino CA, Eberle SE, Fernández D, Guthmann M, Tinelli M, Lombas C, Spitzer E, Demarco I, Montanari A, Basile C, Odella J, Posadas D, Viso M, Villar MV, Pires C, Bevilacqua G, Rubio P, Alonso C, Rossi J, Casanello AL, Rizzi A, Mascardi R, Salvador V, Ardiles N, Zubizarreta P, Cacciavillano W

Open source

DOI: 10.1002/1545-5017.70394
Published: 2026 Aug
Container: Pediatric blood & cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/1545-5017.70394,
  title = {Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina.},
  author = {Felizzia G and Segatori VI and Galluzzo L and Alonso DF and Pinto N and Sobrero V and Varela M and Verón D and Gulino CA and Eberle SE and Fernández D and Guthmann M and Tinelli M and Lombas C and Spitzer E and Demarco I and Montanari A and Basile C and Odella J and Posadas D and Viso M and Villar MV and Pires C and Bevilacqua G and Rubio P and Alonso C and Rossi J and Casanello AL and Rizzi A and Mascardi R and Salvador V and Ardiles N and Zubizarreta P and Cacciavillano W},
  year = {2026},
  journal = {Pediatric blood \& cancer},
  doi = {10.1002/1545-5017.70394},
  url = {https://doi.org/10.1002/1545-5017.70394}
}

RIS

TY  - JOUR
TI  - Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina.
AU  - Felizzia G
AU  - Segatori VI
AU  - Galluzzo L
AU  - Alonso DF
AU  - Pinto N
AU  - Sobrero V
AU  - Varela M
AU  - Verón D
AU  - Gulino CA
AU  - Eberle SE
AU  - Fernández D
AU  - Guthmann M
AU  - Tinelli M
AU  - Lombas C
AU  - Spitzer E
AU  - Demarco I
AU  - Montanari A
AU  - Basile C
AU  - Odella J
AU  - Posadas D
AU  - Viso M
AU  - Villar MV
AU  - Pires C
AU  - Bevilacqua G
AU  - Rubio P
AU  - Alonso C
AU  - Rossi J
AU  - Casanello AL
AU  - Rizzi A
AU  - Mascardi R
AU  - Salvador V
AU  - Ardiles N
AU  - Zubizarreta P
AU  - Cacciavillano W
PY  - 2026
JO  - Pediatric blood & cancer
DO  - 10.1002/1545-5017.70394
UR  - https://doi.org/10.1002/1545-5017.70394
ER  -

APA

G, F., VI, S., L, G., DF, A., N, P., V, S., M, V., D, V., CA, G., SE, E., D, F., M, G., M, T., C, L., E, S., I, D., A, M., C, B., J, O., D, P., M, V., MV, V., C, P., G, B., P, R., C, A., J, R., AL, C., A, R., R, M., V, S., N, A., P, Z., & W, C. (2026). Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina.. Pediatric blood & cancer. https://doi.org/10.1002/1545-5017.70394

Source records

pubmed · retrieved 2026-09-26T01:16:26.692Z